QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=0445342AB54FB9C9C8E9FC6C5F300B7E;jsessionid=AC7337EA37965DE0DF9EC46EE60C3E6B;jsessionid=F95010E1CAC8EB3B84EB352D7B0CBB57;jsessionid=6AE1DFED12C9F08E77597D897BF17C94;jsessionid=7CFDA4B68E1AE4A333C89C7C1250A924;jsessionid=6E4956507CADC21C701C23E83D009673;jsessionid=6B92C31829B0D4CD5CC69BDB70426552;jsessionid=2046C083C6861735951CD9B01693113B (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=0445342AB54FB9C9C8E9FC6C5F300B7E;jsessionid=AC7337EA37965DE0DF9EC46EE60C3E6B;jsessionid=F95010E1CAC8EB3B84EB352D7B0CBB57;jsessionid=6AE1DFED12C9F08E77597D897BF17C94;jsessionid=7CFDA4B68E1AE4A333C89C7C1250A924;jsessionid=6E4956507CADC21C701C23E83D009673;jsessionid=6B92C31829B0D4CD5CC69BDB70426552;jsessionid=2046C083C6861735951CD9B01693113B